Mileutis, an Israeli biopharmaceutical firm transforming the way farmers and veterinarians address various diseases, today announced the appointment of three renowned experts to its Scientific Advisory Board of Directors, chaired by Jose Iscovich.
Dr. William Baker, Vaughn Kubiak, and Dr. Jean-Paul Prieels join Mileutis as the company gears up for large-scale commercialization of its flagship products, Imilac™ - a residue-free intramammary solution for managing, treating, and preventing bovine mastitis at dry-off. They will collaborate with existing Scientific Advisory Board members Thomas D. Overbay and Kobi Lustgarten.
With 30 years of experience in veterinary medicine R&D, Dr. William Baker has worked as a veterinary drug development consultant for Pfizer Animal Health/Zoetis Research and Development. He led Regulatory Affairs for several animal health development programs at Pfizer that achieved FDA approvals, including Dectomax antiparasitic and Draxxin antibiotics for cattle. Baker also served on Zoetis' veterinary medicine leadership team.
Vaughn Kubiak brings over 40 years of global animal health experience, primarily in the development, licensure, and maintenance of veterinary biologics. Throughout his career, Kubiak has contributed to the development and enhancement of conventional and innovative immunological veterinary medicinal products for major species. He held management positions at Zoetis for 17 years in Regulatory Affairs, Biologics Process Development, and Biological Analytical Development.
Dr. Jean-Paul Prieels retired as Senior Vice President of Vaccines R&D at GlaxoSmithKline Biologicals in 2011, after serving as a senior executive for over 23 years. At GlaxoSmithKline, he led the extramural R&D team and was responsible for vaccine R&D preclinical activities in Rixensart, Belgium. Dr. Prieels played a vital role in developing several commercially available vaccines, such as Rotarix, Cervarix, Synflorix, and Shingrix.